Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C

Juanjie Tang, Tanya Novak, Julian Hecker, Gabrielle Grubbs, Fatema Tuz Zahra, Lorenza Bellusci, Sara Pourhashemi, Janet Chou, Kristin Moffitt, Natasha B. Halasa, Stephanie P. Schwartz, Tracie C. Walker, Keiko M. Tarquinio, Matt S. Zinter, Mary A. Staat, Shira J. Gertz, Natalie Z. Cvijanovich, Jennifer E. Schuster, Laura L. Loftis, Bria M. Coates, Elizabeth H. Mack, Katherine Irby, Julie C. Fitzgerald, Courtney M. Rowan, Michele Kong, Heidi R. Flori, Aline B. Maddux, Steven L. Shein, Hillary Crandall, Janet R. Hume, Charlotte V. Hobbs, Adriana H. Tremoulet, Chisato Shimizu, Jane C. Burns, Sabrina R. Chen, Hye Kyung Moon, Christoph Lange, Adrienne G. Randolph and Surender Khurana ()
Additional contact information
Juanjie Tang: Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA
Tanya Novak: Boston Children’s Hospital
Julian Hecker: Brigham and Women’s Hospital and Harvard Medical School
Gabrielle Grubbs: Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA
Fatema Tuz Zahra: Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA
Lorenza Bellusci: Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA
Sara Pourhashemi: Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA
Janet Chou: Boston Children’s Hospital and Harvard Medical School
Kristin Moffitt: Boston Children’s Hospital and Harvard Medical School
Natasha B. Halasa: Vanderbilt University Medical Center
Stephanie P. Schwartz: University of North Carolina at Chapel Hill Children’s Hospital
Tracie C. Walker: University of North Carolina at Chapel Hill Children’s Hospital
Keiko M. Tarquinio: Emory University School of Medicine, Children’s Healthcare of Atlanta
Matt S. Zinter: University of California, San Francisco
Mary A. Staat: Cincinnati Children’s Hospital Medical Center
Shira J. Gertz: Cooperman Barnabas Medical Center
Natalie Z. Cvijanovich: UCSF Benioff Children’s Hospital Oakland
Jennifer E. Schuster: Children’s Mercy Kansas City
Laura L. Loftis: Baylor College of Medicine
Bria M. Coates: Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children’s Hospital of Chicago
Elizabeth H. Mack: Medical University of South Carolina
Katherine Irby: Arkansas Children’s Hospital
Julie C. Fitzgerald: The University of Pennsylvania Perelman School of Medicine
Courtney M. Rowan: Indiana University School of Medicine, Riley Hospital for Children
Michele Kong: University of Alabama at Birmingham
Heidi R. Flori: Mott Children’s Hospital and University of Michigan
Aline B. Maddux: University of Colorado School of Medicine and Children’s Hospital Colorado
Steven L. Shein: Rainbow Babies and Children’s Hospital
Hillary Crandall: University of Utah
Janet R. Hume: University of Minnesota Masonic Children’s Hospital
Charlotte V. Hobbs: University of Mississippi Medical Center
Adriana H. Tremoulet: UCSD School of Medicine
Chisato Shimizu: UCSD School of Medicine
Jane C. Burns: UCSD School of Medicine
Sabrina R. Chen: Boston Children’s Hospital
Hye Kyung Moon: Boston Children’s Hospital
Christoph Lange: Harvard T.H. Chan School of Public Health
Adrienne G. Randolph: Boston Children’s Hospital
Surender Khurana: Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA

Nature Communications, 2022, vol. 13, issue 1, 1-10

Abstract: Abstract Neutralization capacity of antibodies against Omicron after a prior SARS-CoV-2 infection in children and adolescents is not well studied. Therefore, we evaluated virus-neutralizing capacity against SARS-CoV-2 Alpha, Beta, Gamma, Delta and Omicron variants by age-stratified analyses ( 5 years of age. As expected, convalescent pediatric COVID-19 and MIS-C cohorts demonstrate higher neutralization titers than hospitalized acute COVID-19 patients. Overall, children and adolescents show some loss of cross-neutralization against all variants, with the most pronounced loss against Omicron. In contrast to SARS-CoV-2 infection, children vaccinated twice demonstrated higher titers against Alpha, Beta, Gamma, Delta and Omicron. These findings can influence transmission, re-infection and the clinical disease outcome from emerging SARS-CoV-2 variants and supports the need for vaccination in children.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-30649-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30649-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-30649-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().